• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NYU Cancer Institute leads $6.25 million childhood cancer research effort

NYU Cancer Institute leads $6.25 million childhood cancer research effort

October 9, 2013
CenterWatch Staff

Researchers at The Cancer Institute at NYU Langone Medical Center are leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.

Marked by the overproduction of immature white blood cells in the bone marrow, ALL is an aggressive cancer that can kill within months if left untreated. It affects more than 6,000 children in the U.S. every year.

The Leukemia & Lymphoma Society grant is part of the nonprofit's Specialized Center of Research program (SCOR), which brings together some of the brightest and most innovative cancer specialists in the nation to discover new therapies and cures for patients with blood-borne cancers.

The grant encompasses four separate research projects spanning six institutions with a common goal: finding targeted treatments for ALL patients who relapse and derive no benefit from existing chemotherapies. PI William L. Carroll, M.D., the Julie and Edward J. Minskoff professor of pediatrics and director of the Cancer Institute, oversees the SCOR grant.

"Sharper methods to identify genetic mutations in cancerous white blood cells that render chemotherapy powerless will enable us to better identify which patients are at risk for relapse and develop patient-specific cancer therapies designed to root out cancer before resistance takes hold," said Carroll.

Two of the projects will take place at The Cancer Institute. One, led by Dr. Carroll, targets drug resistance in relapsed ALL patients. The other project, led by immunologist and cancer biologist Iannis Aifantis, Ph.D., chair of the department of pathology at NYU Langone and member of The Cancer Institute, seeks to find new drugs to target the cellular cycle of ALL cancer cells.

A team of researchers from St. Jude Children's Research Hospital, the Children's Hospital of Philadelphia, the University of Colorado, Nationwide Children's Hospital and the University of New Mexico will conduct the other two projects: one seeks to identify and treat genetic mutations in ALL cancer cells; the other will develop nanoparticle medications for the targeted treatment of ALL.

The cure rate for children with ALL has increased to nearly 80% in the past four years. However, one in five cases of ALL will relapse, making the disease the leading cause of death among children.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing